Compare

Basilea Pharmaceutica AG/€BSLN

1D1W1M3M6MYTD1Y5YMAX

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
Ticker
€BSLN
Sector
Health
Primary listing
XGAT
Employees
200
Headquarters
Allschwil, Switzerland

BSLN Metrics

BasicAdvanced
€982M
18.02
€4.35
0.32
-

Bulls say / Bears say

Cresemba sales are still accelerating: global in-market sales rose 25% to USD 817 million, triggering a USD 37.5 million European milestone payment. Basilea has raised its 2026 operating-profit forecast to CHF 115 million. (GlobeNewswire, Basilea)
Zevtera offers a second commercial growth opportunity: US hospital access is broadening, with more accounts ordering and repeat orders emerging. Its US market exclusivity runs until April 2034. (Basilea)
External funding helps Basilea advance its pipeline without relying solely on its own cash: BARDA awarded another USD 30 million for fosmanogepix after a trial-enrolment milestone, with further potential funding under the agreement. (Basilea)
Cresemba remains a major earnings driver, but its US exclusivity is expected to end in 2027 and generic entry in Europe is anticipated in 2028. Generic competition could erode royalties before newer products are established. (Edison Group)
Zevtera’s launch has yet to prove it can quickly replace revenue lost elsewhere: one analyst expects its contribution to remain modest until 2027. The antibiotic market is also constrained by stewardship practices that limit use of newer drugs. (Edison Group)
The pipeline may not fill any commercial gap soon: fosmanogepix readouts are targeted for 2028, while ceftibuten-ledaborbactam’s pivotal study is due to start in 2027. Meanwhile, first-half R&D spending rose to CHF 54 million from CHF 38.3 million a year earlier. (Basilea, Basilea)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.